Skip to main content
Fig. 2 | Clinical Epigenetics

Fig. 2

From: Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax

Fig. 2

Overexpression of miR-182 inhibits proliferation and induces apoptosis in ALL cells. A miR-182 expression was measured in NALM-6, REH, and Jurkat cell lines transduced with blank vector (NC) or vector MSCV-miR-182 overexpressing miR-182 (OE). B–D CCK8 activity was measured in NALM-6, REH, and Jurkat cells transduced with NC or OE for the indicated days. E–G Apoptosis was measured in NALM-6, REH, and Jurkat cell lines overexpressing miR-182 or NC by Annexin V and 7-AAD staining. Representative flow cytometry plots (left) and statistical analysis of the percentage of Annexin V+ cells are shown. H A demonstration of the NALM-6-xenografted NSG mouse model. NALM-6 cells were transduced with 182OE or 182NC and transplanted into NSG mice. I hCD45+ cells in the PB of NALM-6-182OE or NALM-6-182NC-xenografted NSG mice were measured. Shown are the representative plots (left) and statistical analysis of the percentage of hCD45+ cells (right). J OS was determined in NALM-6-182OE and NALM-6-182NC-xenografted NSG mice. **P < 0.01; ***P < 0.001

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us